{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:12:45Z","timestamp":1790968365822,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,2,25]],"date-time":"2003-02-25T00:00:00Z","timestamp":1046131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interferon\u2010\u03b1 is the frontline therapy of the majority of chronic myeloid leukemia (CML) patients who are not eligible for bone marrow transplantation. Many patients are treated for long periods, and there is concern about the long\u2010term immune effects of its use. Autoimmune disorders in patients treated with IFN\u2010\u03b1 may be related to the direct immunomodulating properties of IFN or may be linked to a possible toxic effect in target organs, triggering autoimmunity. On the other hand, the immune effects of IFN may play a role in its therapeutic actions. The aims of our study were to assess the incidence of autoimmune phenomena in these patients, and to measure the possible association between the generation of autoimmune phenomena and the antileukemic effect of IFN \u03b1. Therefore, 46 patients with Ph1<jats:sup>+<\/jats:sup> CML in the first chronic phase were studied for the appearance of immune complications, their connection to IFN dose, time of appearance, and the possible association with the response to treatment. Autoimmune abnormalities have been found in 28% of our patients. Moreover, a significant association was found between autoimmune alterations and female sex (<jats:italic>P<\/jats:italic> = 0.02, OR 4.5, 95% CI 1.13\u201317.9) and a longer treatment time (1.6 vs. 4.1 years) (<jats:italic>P<\/jats:italic> = 0.02; OR 1.01, 95% CI 1\u20131.02). The Kaplan\u2013Meier estimated probability of obtaining a cytogenetic response was significantly higher in patients who developed autoimmune alterations (<jats:italic>P<\/jats:italic> = 0.049), and this difference was also evident in Cox's analysis when controlling with other potentially confounding variables (<jats:italic>P<\/jats:italic> = 0.078). We conclude that CML patients treated with IFN alpha have a high incidence of autoimmune phenomenon. Am. J. Hematol. 72:170\u2013176, 2003. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.10282","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T23:06:31Z","timestamp":1048028791000},"page":"170-176","source":"Crossref","is-referenced-by-count":29,"title":["High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon\u2010\u03b1"],"prefix":"10.1002","volume":"72","author":[{"given":"J.L.","family":"Steegmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mart\u00edn\u2010Regueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de la C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Rodriguez","family":"Salvan\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Fern\u00e1ndez Ra\u00f1ada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,2,25]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403243301204"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-4-199502150-00003"},{"key":"e_1_2_1_4_2","first-page":"978","article-title":"Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with CML in chronic phase treated with interferon\u2010alpha. Results of the CML89 trial of the Spanish Collaborative Group on IFN\u2010\u03b12a and CML","volume":"84","author":"Steegmann JL","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90348-3"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2401"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890340212"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.75.6.1484"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1992.tb05852.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339400300605"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199805)58:1<80::AID-AJH15>3.0.CO;2-9"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91502-3"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5"},{"key":"e_1_2_1_14_2","first-page":"S9","article-title":"Effect of \u03b1\u2010interferons on immune function","volume":"24","author":"Herberman RB","year":"1997","journal-title":"Semin Oncol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb03506.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90119-X"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<95::AID-AJH19>3.0.CO;2-0"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90477-U"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.4049\/jimmunol.127.5.2146","article-title":"Interferon acts directly on human B Lymphocytes to modulate immunoglobulin synthesis","volume":"127","author":"H\u00e4rfast B","year":"1981","journal-title":"J Immunol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.4049\/jimmunol.124.5.2436","article-title":"Interferon enhances the expression of FcY receptors","volume":"124","author":"Fridman WH","year":"1980","journal-title":"J Immunol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117473"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3491"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-3-178"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1972595"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92276-X"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37497265349.x"},{"key":"e_1_2_1_28_2","first-page":"258","article-title":"Autoimmune hemolytic anemia during \u03b1 interferon treatment in nine patients with hematological diseases","volume":"81","author":"Andriani A","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.1999.01896.x"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.10282","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.10282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:24:46Z","timestamp":1700277886000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.10282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,25]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1002\/ajh.10282"],"URL":"https:\/\/doi.org\/10.1002\/ajh.10282","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,25]]}}}